NASDAQ:MNOV MediciNova - MNOV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.02 -0.05 (-2.42%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.00▼$2.1350-Day Range$1.95▼$2.5452-Week Range$1.89▼$3.18Volume12,321 shsAverage Volume28,034 shsMarket Capitalization$99.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About MediciNova (NASDAQ:MNOV) StockMediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.Read More Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address MNOV Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comMarch 12, 2023 | americanbankingnews.comStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)March 21, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 9, 2023 | finance.yahoo.comMediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryFebruary 27, 2023 | finance.yahoo.comMNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…February 20, 2023 | finance.yahoo.comMediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and TherapeuticsFebruary 8, 2023 | finance.yahoo.comMediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVIDJanuary 30, 2023 | finance.yahoo.comMediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use DisorderMarch 21, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!January 12, 2023 | finance.yahoo.comMediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed GlioblastomaJanuary 11, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in CanadaJanuary 9, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in BrazilJanuary 5, 2023 | finance.yahoo.comMediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)December 6, 2022 | finance.yahoo.comMediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes FederationDecember 5, 2022 | finance.yahoo.comMediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol AbuseNovember 18, 2022 | finance.yahoo.comMNOV: Well Financed to Get Through Tough Market Conditions…October 13, 2022 | finance.yahoo.comWe Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business GrowthOctober 6, 2022 | reuters.comMNOV.A - MediciNova, Inc. | Stock Price & Latest News | ReutersSeptember 29, 2022 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.comSeptember 16, 2022 | seekingalpha.comMediciNova to get US patent for MN-166 to treat brain cancer - Seeking AlphaSeptember 15, 2022 | globenewswire.comMediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comMediciNova to Participate in the Lytham Partners Fall 2022 Investor ConferenceSeptember 15, 2022 | globenewswire.comMediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma - GlobeNewswireSeptember 14, 2022 | nasdaq.comHealth Care Sector Update for 09/14/2022: MNOV, PNT, MRNA, XLV, IBB - NasdaqSeptember 14, 2022 | finance.yahoo.comMediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of GlioblastomaSeptember 14, 2022 | seekingalpha.comMediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disordersSeptember 14, 2022 | finance.yahoo.comMediciNova Poised To Receive Canadian Patents For Cholesterol CandidatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address MNOV Company Calendar Last Earnings10/26/2020Today3/21/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees11Year Founded2000Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,060,000.00 Net MarginsN/A Pretax Margin-2,628,577.25% Return on Equity-18.73% Return on Assets-17.69% Debt Debt-to-Equity RatioN/A Current Ratio18.51 Quick Ratio18.51 Sales & Book Value Annual Sales$4.04 million Price / Sales24.53 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book1.41Miscellaneous Outstanding Shares49,050,000Free Float40,855,000Market Cap$99.08 million OptionableOptionable Beta0.98 Social Links Key ExecutivesYuichi IwakiPresident, Chief Executive Officer & DirectorJason KrugerChief Financial OfficerKazuko MatsudaDirector & Chief Medical OfficerGeoffrey G. O'BrienVice President & Executive OfficerDavid H. CreanChief Business OfficerKey CompetitorsXBiotechNASDAQ:XBITLarimar TherapeuticsNASDAQ:LRMREyenoviaNASDAQ:EYENCleneNASDAQ:CLNNParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 267,824 shares on 2/15/2023Ownership: 0.546%Millennium Management LLCSold 101,330 shares on 2/15/2023Ownership: 0.513%Virtu Financial LLCBought 25,674 shares on 2/15/2023Ownership: 0.052%Morgan StanleyBought 10,852 shares on 2/15/2023Ownership: 0.046%Squarepoint Ops LLCBought 18,744 shares on 2/15/2023Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions MNOV Stock - Frequently Asked Questions Should I buy or sell MediciNova stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNOV shares. View MNOV analyst ratings or view top-rated stocks. How have MNOV shares performed in 2023? MediciNova's stock was trading at $2.05 on January 1st, 2023. Since then, MNOV stock has decreased by 1.5% and is now trading at $2.02. View the best growth stocks for 2023 here. When is MediciNova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our MNOV earnings forecast. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY). What is MediciNova's stock symbol? MediciNova trades on the NASDAQ under the ticker symbol "MNOV." Who are MediciNova's major shareholders? MediciNova's stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.89%), Jane Street Group LLC (0.55%), Millennium Management LLC (0.51%), JPMorgan Chase & Co. (0.51%), HRT Financial LP (0.37%) and Bank of America Corp DE (0.36%). View institutional ownership trends. How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MediciNova's stock price today? One share of MNOV stock can currently be purchased for approximately $2.02. How much money does MediciNova make? MediciNova (NASDAQ:MNOV) has a market capitalization of $99.08 million and generates $4.04 million in revenue each year. How can I contact MediciNova? MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048. This page (NASDAQ:MNOV) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.